Compare Oklo Inc (OKLO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Recursion Pharmaceuticals Inc — how do they compare? Oklo Inc trades at $42.55 (market cap $8.06B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: Oklo Inc is far larger — about 4.3× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| OKLO | RXRX | |
|---|---|---|
Market Cap | $8.06B | $1.86B |
Sector | Technology | Health |
52-Week High | $174.14 | $6.79 |
52-Week Low | $36.84 | $2.84 |
Enterprise Value | $5.60B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $43.31, up 4.94% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces fundamental challenges, including negative net income margins of -12,625.54% and significant cash burn from operations. Recent news highlights progress in small modular reactor projects but also delays, such as a 14-month setback for its Ohio project noted by Zacks Investment Research on September 1, 2026.
Wall Street maintains a bullish outlook with a $71.58 consensus price target and 71.43% buy ratings, driven by long-term potential in nuclear energy for AI power demand. Key risks include lack of profitability, project execution delays, and high valuation multiples amid substantial cash outflows, requiring careful risk assessment by investors.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
